Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VX-121 Combination Therapy in Adults With Cystic Fibrosis
2018-002496-18Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vanzacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Jan 2019; status: completed.
02
Drugs
vanzacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-002496-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002496-18.